优思灵30R治疗2型糖尿病的疗效及安全性观察

Efficacy and Safety of Yousiling 30R in the Treatment of Type 2 Diabetes

目的观察优思灵30R治疗2型糖尿病的疗效及安全性。方法选取2018年1—7月该院2型糖尿病患者92例,在采用医学营养治疗、运动疗法的基础上,随机分为观察组(46例)和对照组(46例)。对照组给予诺和灵30R治疗,观察组给予优思灵30R治疗,两组患者疗程12周。观察两组患者空腹血糖(FBG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 hPBG)、临床总有效率情况及不良反应情况。结果治疗12周后,两组患者FBG、HbA1c、2 hPBG较治疗前均明显下降,差异有统计学意义(P<0.05),两组间对比差异无统计学意义(P>0.05),两组患者临床总有效率、低血糖发生率之间比较差异无统计学意义(P>0.05)。结论优思灵30R治疗2型糖尿病能显著降低FBG、HbA1c、2hPBG,临床疗效及治疗安全性不劣于诺和灵30R,值得临床推广。

Objective To observe the efficacy and safety of Yousiling 30R in the treatment of type 2 diabetes mellitus. Methods From January to July 2018, Ninety-two patients with type 2 diabetes were randomly divided into observation group （46 cases） and control group （46 cases） on the basis of medical nutrition therapy and exercise therapy. The control group was treated with Nuoheling 30R, the observation group was given Yusiling 30R, and the two groups were treated for 12 weeks. Fasting blood glucose （FBG）, glycosylated hemoglobin （HbAlc）, postprandial 2-hour blood glucose （2 hPBG）, clinical total effective rate and adverse reactions were observed. Results After 12 weeks of treatment, the FBG, HbAlc and 2 hPBG of the two groups were significantly lower than those before treatment, and the difference was statistically significant （P〈 0.05）. There was no significant difference between the two groups （P〉0.05）. There was no significant difference in the clinical total effective rate and the incidence of hypoglycemia between the two groups （P〉0.05）. Conclusion Yousiling 30R can significantly reduce FBG, HbAlc and 2 hPBG in the treatment of type 2 diabetes. The clinical efficacy and safety of treatment are not inferior to Nuoheling 30R, which is worthy of clinical promotion.